USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ARAVASC, INC.
Address:
1520 SAMEDRA ST
SUNNYVALE, CA 94087-8122
Phone:
N/A
URL:
N/A
EIN:
421685148
DUNS:
612223037
Number of Employees:
3
Woman-Owned?:
Yes
Minority-Owned?:
Yes
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $599,999.00 4

Award List:

SBIR Phase I: Drug Eluting Stents to Treat Obstructed Tracheo-Bronchial Lumen Due to Lung Cancer

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase I research project will demonstrate the feasibility of developing a tracheobronchial drug eluting stent (DES) by coating a biodegradable polymeric formulation of Paclitaxel (PTX) on a stent. The stent will provide immediate palliative therapy and… More

Drug-eluting Tracheobronchial Stents to treat Obstruction caused by Lung Cancer

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Airways can be obstructed by a variety of diseases resulting in breathing difficulties and compromised quality of life for the patients. Lung cancer is one of the major diseases causing airway obstruction. According to the American Cancer Society it is the… More

MULTIFUNCTIONAL DRUG-DELIVERY STENT WITH NANOPOROUS COAT

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$199,999.00
Agency:
HHS
Principal Investigator:
Narmada Shenoy – (408) 482-6835
Abstract:
'The overall long-term objective of this proposal is to develop a loco-regional multi-functional theranostic delivery system (MTDS) to treat lung cancer in patients with focal disease, as an adjunct to systemic therapy. The proposed MTDS, releases a clinically proven, cocktail of cancer… More

SBIR PHASE I AWARD

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$200,000.00
Agency:
HHS
Principal Investigator:
Narmada Shenoy – 408-482-6835
Abstract:
Esophageal cancer is a deadly disease with limited treatment options. In addition to modest effects, toxic chemo-therapy drugs cripple patients with debilitating side-effects. This proposal utilizes an Esophageal Theranostic Delivery System (ETDS), to address this clinical need with a multi-modal… More